HCIT, this Vanda trial being covered on CNBC (inst
Post# of 148158
(Total Views: 487)
Posted On: 04/15/2020 5:22:48 PM
HCIT, this Vanda trial being covered on CNBC (instead of covering Leronlimab) would have really frustrated me too, especially since the Vanda drug has huge toxicity issues per the FDA; the FDA stopped one of their trials early for another application because of toxicity concerns.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼